| Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription S Halachmi, E Marden, G Martin, H MacKay, C Abbondanza, M Brown Science 264 (5164), 1455-1458, 1994 | 842 | 1994 |
| The neem tree patent: international conflict over the commodification of life E Marden BC Int'l & Comp. L. Rev. 22, 279, 1999 | 165 | 1999 |
| Risk and regulation: US regulatory policy on genetically modified food and agriculture E Marden BCL Rev. 44, 733, 2002 | 146 | 2002 |
| Plant genetic resources for food and agriculture: opportunities and challenges emerging from the science and information technology revolution M Halewood, T Chiurugwi, R Sackville Hamilton, B Kurtz, E Marden, ... New Phytologist 217 (4), 1407-1419, 2018 | 135 | 2018 |
| Mobilizing crop biodiversity S McCouch, ZK Navabi, M Abberton, NL Anglin, RL Barbieri, M Baum, ... Molecular plant 13 (10), 1341-1344, 2020 | 66 | 2020 |
| Emerging technologies: From hindsight to foresight EF Einsiedel UBC press, 2009 | 34 | 2009 |
| Reflections on FDA draft guidance for products containing nanomaterials: is the abbreviated new drug application (ANDA) a suitable pathway for nanomedicines? M Emily, N Ioanna, B Scott, F Beat The AAPS journal 20, 1-6, 2018 | 31 | 2018 |
| Patent Pools and Genomics: Navigating a Course to Open Science? E Levy, E Marden, B Warren, D Hartell, I Filaté BUJ Sci. & Tech. L. 16, 75, 2010 | 29 | 2010 |
| Alternative intellectual property for genomics and the activity of technology transfer offices: Emerging directions in research R Goulding, E Marden, R Manion, E Levy BUJ Sci. & Tech. L. 16, 194, 2010 | 25 | 2010 |
| Displaced agendas: current regulatory strategies for germline gene therapy E Marden, D Nelkin McGill LJ 45, 461, 2000 | 23 | 2000 |
| Open source drug development: a path to more accessible drugs and diagnostics? E Marden Minn. JL Sci. & Tech. 11, 217, 2010 | 22 | 2010 |
| Sharing and reporting benefits from biodiversity research E Marden, RJ Abbott, F Austerlitz, D Ortiz‐Barrientos, RS Baucom, ... Molecular Ecology 30 (5), 1103-1107, 2021 | 20 | 2021 |
| Intellectual property and sharing regimes in agricultural genomics: Finding the right balance for innovation E Marden, RN Godfrey Drake J. Agric. L. 17, 369, 2012 | 20 | 2012 |
| Recombinant Bovine Growth Hormone and the Courts: In Search of Justice E Marden Drake L. Rev. 46, 617, 1997 | 16 | 1997 |
| International agreements may impact genomic technologies E Marden Nature plants 4 (1), 2-4, 2018 | 14 | 2018 |
| Cloning: a business without regulation E Marden, D Nelkin Hofstra L. Rev. 27, 569, 1998 | 14 | 1998 |
| The new dietary ingredient safety provision of DSHEA: A return to congressional intent S Bass, E Marden American Journal of Law & Medicine 31 (2-3), 285-304, 2005 | 13 | 2005 |
| Pathways to Integration R Ommer, B Wynne, R Downey, E Fisher, E Marden, P Kosseim Genome British Columbia GSEAC Subcommittee on Pathways to Integration, Vancouver, 2011 | 9 | 2011 |
| G. MacKay, H. Abbondanza, C. and Brown. M. 1994 S Halachmi, EM Marden Estrogen receptor-associated proteins: Possible mediators of hormone-induced …, 0 | 8 | |
| The intellectual property–regulatory complex: Overcoming barriers to innovation in agricultural genomics E Marden, RN Godfrey, R Manion UBC Press, 2016 | 7 | 2016 |
